23126-82-1

Usage

Uses

Used in Pharmaceutical Industry:
N4-METHYL-6-CHLORO-5-NITROPYRIMIDIN-4-AMINE is used as a chemical intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
N4-METHYL-6-CHLORO-5-NITROPYRIMIDIN-4-AMINE is used as a chemical intermediate in the production of agrochemicals, such as pesticides and herbicides, to enhance crop protection and yield.
Used in Medicinal Chemistry:
N4-METHYL-6-CHLORO-5-NITROPYRIMIDIN-4-AMINE is utilized as a building block in the design and synthesis of novel compounds with potential medicinal properties, facilitating advancements in drug discovery and development.
Used in Biological Research:
N4-METHYL-6-CHLORO-5-NITROPYRIMIDIN-4-AMINE serves as a valuable compound in biological research, aiding in the study of various biological processes and the development of new therapeutic strategies.
Safety Precautions:
Due to its potentially hazardous nature, N4-METHYL-6-CHLORO-5-NITROPYRIMIDIN-4-AMINE should be handled with caution. It is essential to follow proper safety protocols and regulations for its use and storage to minimize risks and ensure the safety of individuals and the environment.

Upstream product

• 123-91-1 1,4-dioxane 
• 4316-93-2 4,6-dichloro-5-nitropyrimidine 
• 64-19-7 acetic acid 
• 74-89-5 methylamine 

Downstream Products

• 100114-07-6 (6-methoxy-5-nitro-pyrimidin-4-yl)-methyl-amine 
• 91184-45-1 methyl-thiazolo[5,4-d]pyrimidin-7-yl-amine 
• 52602-68-3 6-chloro-N⁴-methylpyrimidine-4,5-diamine 
• 13784-17-3 5-amino-4-methylaminopyrimidine 

Relevant academic research and scientific papers

Palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines with amines

A concise and efficient approach was developed for the synthesis of mono-substituted and di-substituted pyrimidines products via palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines and amines. This synthetic methodology can produce vari

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

Novel 8-arylated purines as inhibitors of glycogen synthase kinase

A series of 8-arylated purine derivatives bearing either an aniline or an alkyl amide at position 6 were found to inhibit glycogen synthase kinase-3,with good selectivity over ten kinases. Molecular modeling studies indicated that the most active compounds (8a and 8e),adopt a planar conformation,close to the shape of AMPPNP in the crystal structure of GSK-3. These compounds are stabilized by hydrophobic contacts between the 8-aromatic group and the protein adenine pocket and by electrostatic contacts.

Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation

The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5-d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said compounds and the use thereof in drugs for the treatment of NAD(P)H oxidases-related diseases and disorders and inhibition of platelet activation.

Purines, Pyrimidines, and Imidazoles. Part 61. Reaction of 6-Alkylamino-4-chloro-5-nitropyrimidines with Diethyl Malonate, Ethyl Cyanoacetate, and Ethyl Acetoacetate and some derived Pyrrolopyrimidines related to the Cytokinins

Reaction of 4-chloro-6-methylamino-5-nitropyrimidine (3d) with diethyl malonate and sodium hydroxide afforded diethyl 6-methylamino-5-nitropyrimidin-4-ylmalonate which was reduced to diethyl 5-amino-6-methylaminopyrimidin-4-ylmalonate and this, with sodiu